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Abstract: YS-121 [2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic 
acid] is the result of target-oriented structural derivatization of pirinixic acid. It is a potent 
dual PPARα/γ-agonist, as well as a potent dual 5-LO/mPGES-1-inhibitor. Additionally, 
recent studies showed an anti-inflammatory efficacy in vivo. Because of its interference 
with many targets, YS-121 is a promising drug candidate for the treatment of inflammatory 
diseases. Ongoing preclinical studies will thus necessitate huge amounts of YS-121. To 
cope with those requirements, we have optimized the synthesis of YS-121. Surprisingly, 
we isolated and characterized byproducts during the resulting from nucleophilic aromatic 
substitution reactions by different tertiary alkylamines at a heteroaromatic halide. These 
amines should actually serve as assisting bases, because of their low nucleophilicity. This 
astonishing fact was not described in former publications concerning that type of reaction 
and, therefore, might be useful for further reaction improvement in general. Furthermore, 
we could develop a proposal for the mechanism of that byproduct formation. 
Keywords: YS-121; pirinixic acid; reaction improvement; nucleophilic aromatic substitution 
reaction at heteroaromatic halide by tertiary alkylamines; byproduct formation mechanism 
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1. Introduction 
Pirinixic acid [1, Wy-14643, 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic 
acid; Figure 1] was discovered in the 1970s, during the development of new agents against 
hypercholesterolemia [1]. Later on, in 1977, it was identified to be a peroxisome proliferator [2]. After 
the discovery of the peroxisome proliferator-activated receptor (PPAR) in 1990 [3], the agonistic 
activity of pirinixic acid at PPARα and PPARγ was detected within the next ten years [4,5]. 
Figure 1. Chemical structure of pirinixic acid. 
pirinixic acid    (1)
Wy-14643
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid
 
YS-121 [2, 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid; Figure 2] is 
the result of target-oriented structural derivatization of pirinixic acid [6]. In YS-121 a hexyl residue 
was introduced in the position  α  to the carboxylic acid group of pirinixic acid. That structural 
modification enhanced PPARα and PPARγ agonism to values in the low micromolar range [EC50 = 1.0 µM 
(α) and 3.6 µM (γ) in a cell-based luciferase reporter gene assay] [6]. 
Figure 2. Chemical structure of YS-121. 
YS-121    (2)
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid 
In addition to its dual agonistic activity at PPARα/γ, further research efforts revealed that YS-121 is 
also a potent dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1, IC50 = 3.9 µM in a 
cell-free assay) and 5-lipoxygenase (5-LO, IC50 = 4.1 µM and 6.5 µM in a cell-based and cell-free 
assay, respectively) with a lack of interference with COX-1 and COX-2 [7,8]. Molecules 2011, 16  10015 
 
 
Based on those findings, more detailed investigations concerning the mechanism of mPGES-1 
inhibition, the selectivity profile and the in vivo activity of YS-121 have been conducted [9]. The 
results of those experimental studies demonstrated that YS-121 inhibits mPGES-1 in a selective, 
concentration-dependent, reversible and noncompetitive manner. Moreover, the above-mentioned lack 
of interference with both isoforms of cyclooxygenase still remains, even in assays performed in human 
whole blood. Additionally, an anti-inflammatory efficacy of YS-121 was shown in vivo [9]. 
In summary, YS-121 is a promising drug candidate, because of its interference with many targets 
involved in inflammatory diseases, but there is still a huge lack of in vivo data concerning dosing, 
pharmacokinetics and effectiveness in humans. 
Ongoing preclinical studies will thus necessitate huge amounts of YS-121. In medicinal chemistry 
the amount of compound needed for biochemical assays to get first in vitro data during structural 
optimization steps is very low. For most assays 3–4 mg are sufficient and the syntheses are planned 
along that required low amount of compound. But the demand for compound rises up to gram scale by 
conducting animal experiments to get first in vivo data of an in vitro hit. To cope with those 
requirements, we have optimized the synthesis of YS-121 resolving the problem of byproduct 
formation during that synthesis conducted in a larger scale. Furthermore, we isolated and characterized 
some byproducts enabling us to develop a proposal for the mechanism of that byproduct formation. 
2. Results and Discussion 
YS-121 was synthesized in a four-step reaction originally published by d’Atri et al. [10] and already 
modified by Koeberle et al. [8]. Here, we modified and optimized that synthesis again to make it 
convenient to synthesize YS-121 in amounts of a few grams. The specific conditions utilized, the 
problem of byproduct formation in step (iii a) and the optimization step to circumvent that byproduct 
formation (iii b) are illustrated in Scheme 1. 
During the first step, 2-mercaptopyrimidine-4,6-diol (3) reacted by a nucleophilic substitution with 
ethyl 2-bromooctanoate in DMF in the presence of triethylamine to form the thioether derivative ethyl 
2-(4,6-dihydroxypyrimidin-2-ylthio)octanoate (4). Chlorination with POCl3 and N,N-diethylaniline 
gave the chlorinated pyrimidine derivative ethyl 2-(4,6-dichloropyrimidin-2-ylthio)octanoate (5). 
Through a nucleophilic aromatic substitution at the pyrimidine core of 5, one chloro group was 
substituted by 2,3-dimethylaniline with triethylamine in EtOH to form the monoaminated derivative 
ethyl 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoate (6, iii a). Additionally, the 
disubstituted byproduct  ethyl 2-(4-(diethylamino)-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)-
octanoate (7) was formed during that step. Changing the assisting base to sodium carbonate in step (iii b), 
lead to a circumvention of that byproduct formation. The last step to get to the desired compound YS-
121 (2) consisted of a saponification of the ethyl ester derivative 6 with LiOH in EtOH to give the 
carboxylic acid derivative 2-(4-chloro-6-(2,3-dimethylphenylamino)-pyrimidin-2-ylthio)octanoic acid (2). 
Because 6 and 7 could not be separated during the purification procedure of step (iii a), 7 was also 
hydrolyzed during step (iv) to give the byproduct (2-(3-(diethylamino)-5-(2,3-dimethylphenylamino)-
phenylthio)octanoic acid (8), which could be separated from 2 and its structure elucidated afterwards. Molecules 2011, 16  10016 
 
 
Scheme 1. Synthesis of YS-121 2 including byproduct formation and optimization step. 
 
Reagents and conditions: (i) ethyl 2-bromooctanoate (1.17 equiv.), triethylamine (1.50 equiv.), 
DMF, RT, 87 h; (ii) POCl3 (18.0 equiv.), N,N-diethylaniline (1.00 equiv.), 90 °C, 45 h; (iii a) 2,3-
dimethylaniline (1.05 equiv.), triethylamine (3.00 equiv.), EtOH, RF, 65 h; (iii b) 2,3-dimethylaniline 
(1.05 equiv.), sodium carbonate (3.00 equiv.), EtOH, RF, 22 h; (iv) LiOH, EtOH, RT, 120 h. 
In comparison to Koeberle et al. [8], several changes have been made to optimize the reaction in 
general. In step (i) the relative amounts of ethyl 2-bromooctanoate and triethylamine as well as the 
reaction temperature were reduced in order to minimize byproduct formation initially caused by a 
dehydrohalogenation of ethyl 2-bromooctanoate leading to a Michael acceptor system that is able to 
react with nucleophiles as well. The dehydrohalogenation is a β-elimination. With regard to the desired 
nucleophilic substitution by 3 on ethyl 2-bromooctanoate, high temperatures and bulky bases raise the 
probability of β-elimination [16]. Because of the lower reaction temperature, longer reaction times 
were required until TLC-control showed total conversion of 3. In step (ii) we reduced the reaction 
temperature to guard the product from decomposition reactions. Because of the lower reaction 
temperature, longer reaction times were required again until TLC-control showed total conversion of 4. 
In steps (iii) and (iv) only the reaction times were expanded. 
Perhaps it would have been possible to reduce the reaction times of all steps, but our aim was first 
and foremost to get the highest yield possible during each respective step. As described above, during 
structural optimization steps in medicinal chemistry, syntheses are planned to get the test compound on 
mg scale, which is sufficient for first in vitro data, but we conducted the reaction steps on a larger scale 
to cope with the rising demand for test compound on gram scale for further in vivo testing. Those 
higher absolute amounts of compounds during synthesis should also have expanded the reaction times. Molecules 2011, 16  10017 
 
 
The challenge of optimizing the synthesis of YS-121 consisted of the low yields of the different 
steps that were primarily based on the high level of byproduct formation. That necessitated huge 
reaction batches, followed by extensive purification procedures and finally led in a large part to those 
low yields. One of those byproducts was formed in high amounts in step (iii a). It was not described in 
former publications concerning that type of reaction [6,8,10-14], also with different aromatic amines as 
nucleophiles, and this forced us to modify the reaction procedure as well as the way of purification. In 
step (iii a) the chlorinated pyrimidine derivative 5 should be monoaminated to 6 by a nucleophilic 
aromatic substitution with 2,3-dimethylaniline. The reaction was conducted with triethylamine in 
EtOH, and the amount of the nucleophile 2,3-dimethylaniline was 1.05 equiv. with regard to 5. After 
the reaction was finished, TLC-control showed the formation of at least four byproducts next to 6. Two 
purification steps by column chromatography with silica gel only led to a rough purification in which 
three of the four byproducts could be separated from the desired product 6 in that step. 
Further conversion of the mixture of step (iii a) in step (iv) again led to the isolation of two different 
compounds. In comparison with the ESI data of step (iii a), mass spectrometry indicated that both 
compounds were converted into carboxylic acids. One of them was the desired final compound 2. We 
tried to separate them by column chromatography, but we were not successful. Afterwards, we switched 
to RP-18 silica gel for column chromatography, which finally allowed a satisfactory separation. 
Furthermore, after termination of the complete synthesis, we found out that purification by RP-18 silica 
gel for column chromatography would have been convenient for the purification in step (iii a) as well. 
During the purification procedure of step (iv), it was possible to isolate the byproduct. The amount 
of the byproduct was 1:1, with regard to the amount of 2. Characterization by the whole lineup of 
structure determination methods (including 
1H-NMR, 
13C-NMR/DEPT, COSY, ROESY, HSQC, 
HMBC and HRMS experiments) suggested a formation of the disubstituted compound 2-(3-
(diethylamino)-5-(2,3-dimethylphenylamino)phenylthio)octanoic acid (8, Figure 3). Analytical data of 
8 are given in the Experimental section. 
Figure 3. Chemical structure of the isolated byproduct 8. 
 
As far as the formation of byproduct 8 is concerned, a disubstitution would have only been possible 
in step (iii a), if diethylamine or diethylamine-related reactive intermediates had been present next to 
2,3-dimethylaniline as nucleophiles as well. Either that byproduct formation is the result of a Molecules 2011, 16  10018 
 
 
diethylamine impurity of the used commercially available reagents triethylamine, 2,3-dimethylaniline 
or EtOH in step (iii a) or it is a further indication that triethylamine could react as a nucleophile during 
nucleophilic aromatic substitution reactions at heteroaromatic halides as previously described by 
Matsumoto et al. [15]. 
To get deeper insights into the mechanism leading to the formation of byproduct 8, we repeated step 
(iii a) with triethylamine as assisting base and could reproduce that byproduct formation in two 
reaction batches reacted independently from each other. Afterwards, we tried to isolate other 
byproducts of that reaction that could tell us something about the mechanism leading to 8. In fact, we 
were successful, because we could isolate the stable intermediate 6-(2,3-dimethylphenylamino)-2-(1-
ethoxy-1-oxooctan-2-ylthio)-N,N,N-triethylpyrimidin-4-aminium (9, Figure 4), the precursor of 
compound 7. 
Figure 4. Chemical structure of the isolated byproduct 9. 
 
Compound 9  is a quaternary ammonium cation. Furthermore, both chlorines were already 
substituted, so the formation of 9 probably lead in the first stage to a Meisenheimer complex 
intermediate 10 (Figure 5) that was formed by a nucleophilic attack of triethylamine leading in second 
stage to an elimination of a chloride ion. 
Figure 5. Chemical structure of the Meisenheimer complex intermediate 10. 
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Additionally, other byproducts were formed in step (iii a), but we were not able to separate them 
satisfactorily. Because the insights into the mechanism of byproduct formation were still not sufficient, 
we repeated step (iii a) again, now with N-methylpyrrolidine as assisting base as a member of cyclic 
tertiary alkylamines. Again, we tried to isolate byproducts giving us new insights into the mechanism 
of byproduct formation and again, we were successful. We could isolate two byproducts telling us a lot 
about the mechanism. First, we could isolate the byproduct ethyl 2-(4-ethoxy-6-(pyrrolidin-1-
yl)pyrimidin-2-ylthio)octanoate (11, Figure 6). 
Figure 6. Chemical structure of the isolated byproduct 11. 
N
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isolated byproduct 11
ethyl 2-(4-ethoxy-6-(pyrrolidin-1-yl)pyrimidin-2-ylthio)octanoate 
In comparison to compound 5, several changes took place at the pyrimidine core. Both chlorines 
were substituted, the first by N-methylpyrrolidine and the second by the solvent ethanol. During 
byproduct formation, N-methylpyrrolidine lost its methyl group. But that byproduct as well as 
byproduct 8 could not tell us how in both cases the quaternary ammonium cation had lost its fourth 
carbon residue leading to a N,N-dialkylaminyl substituent at the pyrimidine core. In summary, during 
formation of byproduct 11, one equivalent of methyl chloride and one equivalent of hydrochloric acid 
were eliminated. 
A deeper insight into the incidents taking place at the pyrrolidinyl residue was provided by the 
isolated byproduct ethyl 2-(4-((4-chlorobutyl)(methyl)amino)-6-ethoxypyrimidin-2-ylthio)octanoate (12, 
Figure 7). 
During formation of byproduct 12 the pyrrolidine ring was opened but no carbon residue was 
eliminated. In summary, only one equivalent of hydrochloric acid was eliminated through a solvolytic 
reaction with ethanol, but the terminally chlorinated n-butyl residue as well as the methyl residue of 
the  N,N-dialkylaminyl substituent at the pyrimidine core provided evidence for the ring opening 
mechanism. That ring opening probably had happened either through a nucleophilic attack of a 
chloride ion during the state of a Meisenheimer complex intermediate 13 as a concerted process 
together with the elimination of the chloride ion from the pyrimidine core or during the state of a 
quaternary ammonium cation such as 1-(6-ethoxy-2-(1-ethoxy-1-oxooctan-2-ylthio)pyrimidin-4-yl)-1-
methylpyrrolidinium (14, Figure 8) as a non-concerted process. 
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Figure 7. Chemical structure of the isolated byproduct 12. 
 
Figure 8. Chemical structures of not isolated hypothetical intermediates of the respective 
intermediate stages during reaction with N-methylpyrrolidine. 
 
We could not isolate either of the two intermediates, but because we could isolate byproduct 9, so 
the non-concerted process of a nucleophilic attack of a chloride ion after elimination from the 
pyrimidine core seems to be more likely. The solvolytic reaction at the pyrimidine core also stresses 
that last presumption. Only during the stage of the quaternary ammonium cation, a nucleophilic attack 
of the solvent is possible and catalyzed, because N-methylpyrrolidine is a good leaving group in that 
case. The potential of tertiary amines to catalyze nucleophilic substitution reactions at aromatic 
heterocycles was already described in the literature [17]. The fact that we could not isolate solvolytic 
reaction byproducts from the reaction with triethylamine could be due to the steric hindrance at the 
tertiary ammonium cation 9 preventing a nucleophilic attack of the solvent. 
Another interesting fact is that during reaction with N-methylpyrrolidine we could not isolate any 
amount of desired compound 6 at all, although we had not changed the relative amounts of educts. 
That suggests a higher nucleophilic potential of N-methylpyrrolidine as well as a higher potential of  
N-methylpyrrolidine to catalyze solvolytic reactions at the chlorinated pyrimidine core in comparison 
to triethylamine. Molecules 2011, 16  10021 
 
 
To sum it up, the following Scheme 2 depicts our proposal for the mechanism of byproduct 
formation based on the isolated and characterized byproducts 8, 9, 11 and 12 during step (iii a) with 
two different tertiary alkylamines as assisting bases: 
Scheme 2. Postulated mechanism of byproduct formation. 
 
(i) A nucleophilic attack of a tertiary alkylamine at a 4,6-di-chlorinated pyrimidine core 15 leads to 
a Meisenheimer complex intermediate 16; (ii) afterwards, a chloride ion is eliminated leading through 
rearomatization to a quaternary ammonium cation intermediate stage 17; (iii) finally, a nucleophilic 
attack by a chloride ion at any carbon residues of the quaternary N,N,N-trialkylaminyl substituent of 17 
leads to a monochlorinated pyrimidine core with a N,N-dialkylaminyl substituent 18. 
With the isolation of byproduct 9 and the support from isolated byproducts 11 and 12 we can state 
that formation of byproduct 8 during step (iii a) was due to a direct nucleophilic attack of the tertiary 
alkylamine triethylamine at the chlorinated pyrimidine core of 5. Because triethylamine and other tertiary 
alkylamines are broadly used as assisting bases during nucleophilic aromatic substitution reactions due 
to their low nucleophilicity, our results put their use into question during that type of reactions. 
As stated above, the formation of that sort of byproducts was not described in former publications 
about that type of reaction showing the synthesis of pirinixic acid derivatives. One cause of the fact 
that byproduct 8 is apparently formed exclusively during reaction batches on a larger scale could 
probably be the higher concentration of triethylamine during step (iii a) that has raised the probability 
of a nucleophilic attack of triethylamine at the chlorinated pyrimidine core. Therefore, we think that it 
could be useful to lower the concentration of triethylamine in step (iii a) or to change the assisting base Molecules 2011, 16  10022 
 
 
triethylamine to sodium carbonate as depicted in step (iii b) and as previously described by   
Rau et al. [6] and Popescu et al. [11] to avoid the formation of byproduct 8. 
We checked that last proposal for effectiveness during step (iii b) and indeed, byproducts were 
formed to a lesser extent. That made the purification procedure less complex. Therefore, we succeeded 
in optimizing reaction step (iii a) by changing the assisting base triethylamine to sodium carbonate as 
depicted in step (iii b). So, all forms of reactions utilizing inorganic assisting bases during nucleophilic 
aromatic substitution reactions at heteroaromatic halides seem to be more suitable than reactions using 
tertiary alkylamines as assisting bases. 
3. Experimental 
3.1. General 
Compounds and Chemistry. All commercial chemicals and solvents were of reagent grade and were 
used without further purification. For step (i), commercially available triethylamine was distilled after 
refluxing over KOH. All reactions were carried out in an argon atmosphere and compounds 2, 4, 5, 6, 
8,  9,  11 and 12 were permanently stored under argon after their purification. The structures of 
compounds  2,  4,  5,  6,  8,  9,  11 and 12 were confirmed by 
1H-NMR spectroscopy and mass 
spectrometry (ESI). The structures of final compound 2 and byproducts, 8,  9,  11, and 12 were 
additionally confirmed by 
13C-NMR spectroscopy and in part by high-resolution mass spectrometry 
(HRMS). Furthermore, the purity of compound 2 was determined by combustion analysis and high 
pressure liquid chromatography (HPLC) analysis and was 99%. 
1H- and 
13C-NMR spectra were measured in DMSO-d6 on a Bruker AM 250, DPX 250, AV 300 or 
AV 400 spectrometer (Bruker, Rheinstetten, Germany). For correct correlation of 
13C-NMR signals to 
the respective carbon atom in compound 2 and for structure determination of byproduct 7 in general, 
13C
  distortionless enhancement by polarization transfer (DEPT), 
1H-
1H correlation spectroscopy 
(COSY), 
1H-
1H rotating frame nuclear overhauser effect spectroscopy (ROESY), 
1H-
13C heteronuclear 
single quantum coherence (HSQC) and 
1H-
13C heteronuclear multiple bond correlation (HMBC) 
experiments were conducted. They were also performed on the spectrometers mentioned above. 
Chemical shifts are reported in parts per million (ppm) using tetramethylsilane (TMS) as an internal 
standard. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet,  
t = triplet, q = quartet, m = multiplet, br = broad. Mass spectra were obtained on a Fisons Instruments 
VG Platform II spectrometer measuring in the positive- or negative-ion mode (ESI-MS system, Fisons 
Instruments, Manchester, Great Britain). High-resolution mass spectra (HRMS) were recorded on a 
Thermo Scientific MALDI LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, MA, USA). 
Combustion analysis was performed by the Microanalytical Laboratory of the Institute of Organic 
Chemistry and Chemical Biology, Goethe University Frankfurt, on a Foss Heraeus CHN-O-rapid 
elemental analyzer (Heraeus, Hanau, Germany). High pressure liquid chromatography (HPLC) 
analysis was carried out on a Waters instrument (Waters, Milford, CT, USA) consisting of a Waters 
600 controller, an In-Line Degasser AF, a Waters 717plus autosampler and a Waters 2487 dual λ 
absorbance detector. The utilized detection wavelengths were 247, 254 and 290 nm. The column used 
was a MultoHigh Phenyl-5 µm column, 250 × 4 mm (CS Chromatographie, Langerwehe, Germany). Molecules 2011, 16  10023 
 
 
The mobile phase gradient used consisted of 2 phases (MeOH = phase A, Milli-Q distillate 0.1% 
formic acid = phase B) starting with 10% phase A up to 100% phase A within 45 min. The used flow 
rate was 1 mL/min and the separation temperature was set at 25 °C. Reactions were monitored by  
thin-layer chromatography that was carried out on Merck TLC silica gel plates 60 F254 and RP-18 F254 s 
(Merck, Darmstadt, Germany) using UV light as visualizing agent. Macherey Nagel silica gel 60, 
particle size 0.040–0.063 mm/230–400 mesh ASTM (Macherey Nagel, Düren, Germany) and   
Sigma-Aldrich octadecyl-functionalized silica gel, particle size 200–400 mesh, extent of loading:   
20–22% (Sigma-Aldrich, St. Louis, MO, USA) were used for column chromatography. The synthesis 
of YS-121 followed the route originally published by d’Atri et al. [10] and already modified by 
Koeberle et al. [8]. That synthesis was modified and optimized again in some cases to be convenient to 
resolve the problem of byproduct formation during that synthesis conducted in a larger scale. 
3.2. Ethyl 2-(4,6-Dihydroxypyrimidin-2-ylthio)octanoate (4) 
Step (i). 2-Mercaptopyrimidine-4,6-diol (3; 30.0 g, 208 mmol, 1.00 equiv.) was dissolved in 
anhydrous DMF (150 mL) under heating. Triethylamine (31.5 g, 312 mmol, 1.50 equiv.) was added at 
23 °C through a dripping funnel, followed by ethyl 2-bromooctanoate (61.4 g, 244 mmol, 1.17 equiv.). 
After stirring at room temperature for 87 h (TLC control), the DMF was evaporated under reduced 
pressure. The residue was suspended in water and extracted with EtOAc. The combined organic layers 
were washed with brine, dried with MgSO4, filtered and evaporated under reduced pressure. The crude 
product was recrystallized from EtOAc/n-hexane to give 4 (27.3 g, 42%) as a white solid. Rf = 0.64 
(silica gel, EtOAc-MeOH 3:1); 
1H-NMR [250.13 MHz, (CD3)2SO]: δ = 0.86 (t, 3H, CH3-Hex, J = 6.8 Hz), 
1.17 (t, 3H, OCH2CH3, J = 7.0 Hz), 1.25–1.44 (m, 8H, CH2-Hex), 1.73–1.94 (m, 2H, CH2-Hex), 4.14 
(q, 2H, OCH2, J = 7.3 Hz), 4.52 (t, 1H, SCH, J = 7.3 Hz), 5.25 (s, 1H, Pyr-5H), 11.81 (br s, 2H, OH); 
MS (ESI+): m/e = 315.1 [M + H]
+. 
3.3. Ethyl 2-(4,6-Dichloropyrimidin-2-ylthio)octanoate (5) 
Step (ii). POCl3 (219 g, 1.43 mol, 18.0 equiv.) was added through a dripping funnel at 0 °C to the 
thioether derivative 4 (25.0 g, 79.5 mmol, 1.00 equiv.) resulting from step (i), followed by   
N,N-diethylaniline (11.9 g, 79.5 mmol, 1.00 equiv.) at 0 °C. That mixture was stirred at 90 °C for 45 h 
(TLC control). Then, excess POCl3 was distilled off at atmospheric pressure, and the resulting oil was 
poured onto crushed ice. The aqueous solution was extracted with EtOAc, and the combined organic 
layers were washed with diluted HCl, saturated NaHCO3 solution and brine. Then, the organic layer 
was dried over MgSO4, filtered and evaporated under reduced pressure. The crude product was 
purified by column chromatography (silica gel, n-hexane-EtOAc 5:1) to give 5 (24.5 g, 88%) as a red 
oil. Rf = 0.6 (silica gel, n-hexane-EtOAc 5:1); 
1H-NMR [400.13 MHz, (CD3)2SO]: δ = 0.86 (t, 3H, 
CH3-Hex, J = 7.2 Hz), 1.20 (t, 3H, OCH2CH3, J = 6.8 Hz), 1.24–1.34 (m, 6H, CH2-Hex), 1.36–1.43 
(m, 2H, CH2-Hex), 1.79–1.97 (m, 2H, CH2-Hex), 4.15 (q, 2H, OCH2, J = 7.2 Hz), 4.37 (t, 1H, SCH,  
J = 7.2 Hz), 7.75 (s, 1H, Pyr-5H); MS (ESI+): m/e = 351.1 [M + H]
+. 
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3.4. Ethyl 2-(4-Chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoate (6) and 2-(4-Chloro-
6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic Acid (2) 
Step (iii a). A solution of the chlorinated pyrimidine derivative 5 (18.7 g, 53.2 mmol, 1.00 equiv.) 
obtained from step (ii), triethylamine (16.2 g, 160 mmol, 3.00 equiv.) and 2,3-dimethylaniline (6.78 g, 
55.9 mmol, 1.05 equiv.) in EtOH (62.5 mL) was refluxed under stirring for 65 h (TLC control). Then, 
EtOH and excess triethylamine were evaporated under reduced pressure. The residue was dissolved in 
EtOAc, and the organic layer was extracted with diluted HCl, saturated NaHCO3 solution and brine. 
Then, the organic layer was dried over MgSO4, filtered and evaporated under reduced pressure. The 
crude product was roughly purified by column chromatography (silica gel, n-hexane-EtOAc 10:1) to 
give a mixture of the desired compound 6 together with one byproduct as a yellow oil (14.0 g). MS 
(ESI+): m/e = 436.2 [M + H]
+, byproduct: MS (ESI+): m/e = 473.3 [M + H]
+. That mixture was used 
for step (iv) without further purification. 
After completion of step (iv), further purification of 500 mg of that mixture by column 
chromatography (RP-18 silica gel, acetonitrile-water 4:1) gave the desired compound 6 (210 mg) as a 
yellow oil. Therefore, purification by RP-18 silica gel is already useful and applicable at that stage of 
synthesis. By extrapolating the result of RP-18 column chromatography of 500 mg up to 14.0 g, a yield 
of 5.88 g, 25% of 6 could have been achievable. Rf = 0.2 (silica gel, n-hexane-EtOAc 10:1);   
1H-NMR (250.13 MHz, (CD3)2SO): δ = 0.83 (t, 3H, CH3-Hex, J = 7.0 Hz), 1.15 (t, 3H, OCH2CH3,  
J = 7.0 Hz), 1.16–1.34 (m, 8H, CH2-Hex), 1.63–1.84 (m, 2H, CH2-Hex), 2.05 (s, 3H, Ph-2-CH3), 2.26 
(s, 3H, Ph-3-CH3), 4.08 (q, 2H, OCH2, J = 7.3 Hz), 4.25 (t, 1H, SCH, J = 7.3 Hz), 6.20 (s, 1H, Pyr-5H), 
7.06-7.13 (m, 3H, Ph-4,5,6-H), 9.51 (br s, 1H, NH); MS (ESI+): m/e = 436.2 [M + H]
+. 
Step (iv). The mixture of 6 and one byproduct (13.5 g) obtained in step (iii a) was dissolved in 
EtOH (420 mL) at room temperature. An approximate excess of LiOH (2.61 g, 109 mmol) was added, 
and the resulting mixture was stirred at room temperature for 120 h (TLC control). Then, EtOH was 
removed under reduced pressure, and the obtained residue was dissolved in water under heating, while 
low amounts of MeOH were added. The solution was acidified with diluted HCl, and the precipitate 
was filtered, washed to neutrality with water and then with n-hexane. A solution of the precipitate in 
EtOAc was dried over MgSO4, filtered and evaporated under reduced pressure. The crude product was 
purified by column chromatography (RP-18 silica gel, acetonitrile-water 4:1). Finally a solution of the 
purified product in EtOAc was extracted with diluted HCl, washed to neutrality with water and was 
dried over MgSO4. After filtration, the solvent was evaporated under reduced pressure and the product 
was precipitated from EtOAc/n-hexane. After two weeks at 26 °C, the solid product was filtered and 
was washed with n-hexane. In the end 2.00 g of the carboxylic acid derivative 2 were obtained as a 
pale yellow solid. By including the extrapolated content of 6 in the mixture used in that step, a yield of 
38% was achieved. Rf = 0.4 (silica gel, EtOAc); 
1H-NMR [250.13 MHz, (CD3)2SO]: δ = 0.85 (t, 3H, 
CH3-Hex, J = 6.3 Hz), 1.10–1.37 (m, 8H, CH2-Hex), 1.59–1.91 (m, 2H, CH2-Hex), 2.08 (s, 3H, Ph-2-
CH3), 2.28 (s, 3H, Ph-3-CH3), 4.23 (br t, 1H, SCH), 6.21 (s, 1H, Pyr-5H), 7.08–7.16 (m, 3H, Ph-4,5,6-H), 
9.51 (br s, 1H, NH), 12.82 (br s, 1H, COOH); 
13C-NMR [62.90 MHz, (CD3)2SO]: δ = 13.85 (CH3-Hex), 
13.99 (Ph-2-CH3), 20.06 (Ph-3-CH3), 21.90 (CH2-Hex), 26.38 (CH2-Hex), 28.08 (CH2-Hex), 30.94 
(CH2-Hex), 31.95 (CH2-Hex), 46.93 (SCH), 98.90 (Pyr-5-C), 123.99 (Ph-6-C), 125.67 (Ph-5-C), 
127.83 (Ph-4-C), 132.33 (Ph-2-C), 135.61 (Ph-3-C), 137.59 (Ph-1-C), 157.73 (Pyr-4-C), 162.16 (Pyr-2-C), Molecules 2011, 16  10025 
 
 
169.63 (Pyr-6-C), 172.47 (COOH); MS (ESI+): m/e = 408.1 [M + H]
+; HRMS (MALDI): calcd. for 
C20H27ClN3O2S
+ [M + H]
+ = 408.1507, found 408.1509; Anal. Calcd. C20H26ClN3O2S C, H, N: Calc.  
C 58.88, H 6.42, N 10.30, found C 59.12, H 6.52, N 10.15. 
3.5. Analytical data of (2-(3-(Diethylamino)-5-(2,3-dimethylphenylamino)phenylthio)octanoic Acid (8) 
During purification procedure of step (iv), 8 could be isolated as well as a pale, yellow solid. Rf = 0.6 
(silica gel, EtOAc); 
1H-NMR [250.13 MHz, (CD3)2SO]: δ = 0.85 (t, 3H, CH3-Hex, J = 6.8 Hz), 1.05 (t, 
6H, N(CH2CH3)2, J = 7.0 Hz), 1.19–1.41 (m, 8H, CH2-Hex), 1.69–1.88 (m, 2H, CH2-Hex), 2.08 (s, 
3H, Ph-2-CH3), 2.26 (s, 3H, Ph-3-CH3), 3.27–3.43 (m, 4H, N(CH2CH3)2), 4.25 (t, 1H, SCH, J = 7.5), 
5.19 (s, 1H, Pyr-5H), 6.98–7.15 (m, 3H, Ph-4,5,6-H), 8.38 (br s, 1H, NH), 12.74 (br s, 1H, COOH); 
 
13C- NMR [62.90 MHz, (CD3)2SO]: δ = 12.79 (N(CH2CH3)2), 13.84 (CH3-Hex), 14.01 (Ph-2-CH3), 
20.16 (Ph-3-CH3), 21.92 (CH2-Hex), 26.80 (CH2-Hex), 28.30 (CH2-Hex), 31.07 (CH2-Hex), 32.42   
(CH2-Hex), 41.49 (N(CH2CH3)2), 46.96 (SCH), 77.39 (Pyr-5-C), 123.43 (Ph-6-C), 125.32 (Ph-5-C), 
126.38 (Ph-4-C), 131.59 (Ph-2-C), 137.13 (Ph-3-C), 137.52 (Ph-1-C), 160.42 (Pyr-4-C), 161.80   
(Pyr-2-C), 167.63 (Pyr-6-C), 173.29 (COOH); MS (ESI+): m/e = 445.3 [M + H]
+; HRMS (MALDI): 
calcd. for C24H37N4O2S
+ [M + H]
+ = 445.2632, found 445.2635. 
3.6. 6-(2,3-Dimethylphenylamino)-2-(1-ethoxy-1-oxooctan-2-ylthio)-N,N,N-triethylpyrimidin-4-
aminium (9) 
A solution of the chlorinated pyrimidine derivative 5 (400 mg, 1.14 mmol, 1.00 equiv.) obtained 
from step (ii), triethylamine (346 mg, 3.42 mmol, 3.00 equiv.) and 2,3-dimethylaniline (145 mg,   
1.20 mmol, 1.05 equiv.) in EtOH (1.33 mL) was refluxed under stirring for 14 h (TLC control). Then, 
EtOH and excessive triethylamine were evaporated under reduced pressure. The residue was dissolved 
in EtOAc, and the organic layer was extracted with diluted HCl, saturated NaHCO3 solution and brine. 
Then, the organic layer was dried over MgSO4, filtered and evaporated under reduced pressure. 
Compound 9 was precipitated from EtOAc/n-hexane at 26 °C to give 9 (70.0 mg, 12%) as a colorless 
solid. 
1H-NMR [400.13 MHz, (CD3)2SO]: δ = 0.86 (t, 3H, CH3-Hex, J = 6.7 Hz), 1.11–1.39 (m, 20H, 
N(CH2CH3)3, OCH2CH3, CH2-Hex), 1.71–1.89 (m, 2H, CH2-Hex), 2.10 (s, 3H, Ph-2-CH3), 2.30 (s, 
3H, Ph-3-CH3), 3.65–3.82 (m, 6H, N(CH2CH3)3), 4.04–4.16 (m, 2H, OCH2), 4.30 (br t, 1H, SCH),  
6.91–7.24 (m, 4H, Pyr-5H, Ph-4,5,6-H), 10.22 (s, 1H, NH); 
13C-NMR [75.44 MHz, (CD3)2SO]:  
δ = 7.68 (N(CH2CH3)3), 13.82 (CH3-Hex), 13.92 (OCH2CH3), 14.18 (Ph-2-CH3), 20.08 (Ph-3-CH3), 
21.85 (CH2-Hex), 26.39 (CH2-Hex), 28.08 (CH2-Hex), 30.87 (CH2-Hex), 30.95 (CH2-Hex), 47.07 
(SCH), 53.41 (N(CH2CH3)3), 61.05 (COOCH2), 95.39 (Pyr-5-C), 123.57 (Ph-6-C), 125.63 (Ph-5-C), 
127.94 (Ph-4-C), 131.92 (Ph-2-C), 135.42 (Ph-3-C), 137.59 (Ph-1-C), 159.10 (Pyr-4-C), 162.76   
(Pyr-2-C), 170.26 (Pyr-6-C), 171.21 (COOCH2CH3); MS (ESI+): m/e = 502.3. 
3.7. Ethyl 2-(4-Ethoxy-6-(pyrrolidin-1-yl)pyrimidin-2-ylthio)octanoate (11) and Ethyl 2-(4-((4-chloro-
butyl)(methyl)amino)-6-ethoxypyrimidin-2-ylthio)octanoate (12) 
A solution of the chlorinated pyrimidine derivative 5 (200 mg, 0.569 mmol, 1.00 equiv.) obtained 
from step (ii), N-methylpyrrolidine (145 mg, 1.71 mmol, 3.00 equiv.) and 2,3-dimethylaniline (72.4 mg, Molecules 2011, 16  10026 
 
 
0.598 mmol, 1.05 equiv.) in EtOH (0.667 mL) was refluxed under stirring for 21 h (TLC control). 
Then, EtOH and excessive N-methylpyrrolidine were evaporated under reduced pressure. The residue 
was dissolved in EtOAc, and the organic layer was extracted with diluted HCl, saturated NaHCO3 
solution and brine. Then, the organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude product was roughly purified by column chromatography (silica gel,   
n-hexane-EtOAc 20:1) to give a mixture of compound 11 and compound 12. To separate both 
compounds a second column chromatography step followed using silica gel and an eluent gradient of 
n-hexane-EtOAc from 50:1 to 20:1 to give 11 (8.0 mg, 4%) as a colorless oil and 12 (10.0 mg, 4%) as 
a light yellow oil. 
Compound  11. Rf = 0.4 (silica gel, n-hexane-EtOAc 10:1); 
1H-NMR [400.13 MHz, (CD3)2SO]:  
δ = 0.86 (t, 3H, CH3-Hex, J = 6.8 Hz), 1.17 (t, 3H, COOCH2CH3, J = 7.1 Hz), 1.25–1.43 (m, 11H, 
ArOCH2CH3, CH2-Hex), 1.75–1.99 (m, 6H, CH2-Hex, Pyrrolidine-2-CH2, Pyrrolidine-3-CH2),  
3.24–3.42 (m, 4H, Pyrrolidine-1-CH2, Pyrrolidine-4-CH2), 4.06–4.16 (m, 2H, COOCH2), 4.21–4.26 
(m, 2H, ArOCH2), 4.35 (t, 1H, SCH, J = 7.3 Hz), 5.42 (s, 1H, Pyr-5H); 
13C-NMR [62.90 MHz, 
(CD3)2SO]:  δ = 13.80 (CH3-Hex), 13.93 (COOCH2CH3), 14.43 (ArOCH2CH3), 21.89 (CH2-Hex), 
24.62 (Pyrrolidine-2-CH2, Pyrrolidine-3-CH2), 26.62 (CH2-Hex), 28.11 (CH2-Hex), 30.93 (CH2-Hex), 
31.37 (CH2-Hex), 46.07 (Pyrrolidine-1-CH2, Pyrrolidine-4-CH2), 46.88 (SCH), 60.70 (COOCH2), 
61.43 (ArOCH2), 81.23 (Pyr-5-C), 161.02 (Pyr-2-C), 167.38 (Pyr-4-C), 168.39 (Pyr-6-C), 171.72 
(COOCH2CH3); MS (ESI+): m/e =396.2. 
Compound  12. Rf = 0.3 (silica gel, n-hexane-EtOAc 10:1); 
1H-NMR [400.13 MHz, (CD3)2SO]:  
δ = 0.86 (t, 3H, CH3-Hex, J = 6.8 Hz), 1.17 (t, 3H, COOCH2CH3, J = 7.1 Hz), 1.25–1.43 (m, 11H, 
ArOCH2CH3, CH2-Hex), 1.59–1.99 (m, 6H, CH2-Hex, NCH2CH2CH2CH2Cl), 2.95 (s, 1H, NCH3), 
3.43–3.59 (m, 2H, NCH2CH2CH2CH2Cl), 4.06–4.16 (m, 2H, COOCH2), 4.21–4.26 (m, 2H, ArOCH2), 
4.34 (t, 1H, SCH, J = 7.3 Hz), 5.60 (s, 1H, Pyr-5H); 
13C-NMR [62.90 MHz, (CD3)2SO]: δ = 13.80 
(CH3-Hex), 13.93 (COOCH2CH3), 14.43 (ArOCH2CH3), 21.89 (CH2-Hex), 24.13 (NCH2CH2CH2CH2Cl), 
26.62 (CH2-Hex), 28.09 (CH2-Hex), 29.36 (NCH2CH2CH2CH2Cl), 30.93 (CH2-Hex), 31.32   
(CH2-Hex), 35.13 (NCH3), 45.09 (NCH2CH2CH2CH2Cl), 46.79 (SCH), 47.48 (NCH2CH2CH2CH2Cl), 
60.74 (COOCH2),  61.51 (ArOCH2),  80.63 (Pyr-5-C), 162.83 (Pyr-2-C), 167.31 (Pyr-4-C), 168.98   
(Pyr-6-C), 171.71 (COOCH2CH3); MS (ESI+): m/e = 446.2. 
3.8. Ethyl 2-(4-Chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoate (6) 
Step (iii b). A solution of the chlorinated pyrimidine derivative 5 (200 mg, 0.569 mmol, 1.00 equiv.) 
obtained from step (ii), sodium carbonate (180 mg, 1.71 mmol, 3.00 equiv.) and 2,3-dimethylaniline 
(72.4 mg, 0.598 mmol, 1.05 equiv.) in EtOH (1.33 mL) was refluxed under stirring for 22 h (TLC control). 
Then, excessive sodium carbonate was filtrated and EtOH was evaporated under reduced pressure. The 
residue was dissolved in EtOAc, and the organic layer was extracted with diluted HCl, saturated NaHCO3 
solution and brine. Then, the organic layer was dried over MgSO4, filtered and evaporated under reduced 
pressure. The crude product was purified by column chromatography (silica gel, n-hexane-EtOAc 
10:1) to give compound 6 (92 mg, 35%) as a yellow oil. For analytical data of 6, see 3.4. 
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4. Conclusions 
Here, we have demonstrated that syntheses conducted in a larger scale can generate problems and 
byproducts that did not appear at these syntheses at the original small scale, but we also show that it is 
possible to resolve these problems by a change in the purification procedure or reagents used as well as 
in the way of synthesis and thus obtained clean compounds. By conducting the described synthesis, it 
was possible to generate up to 2.00 g of YS-121 (2) as a pure compound for use in ongoing preclinical 
studies. By a change of the assisting base triethylamine to sodium carbonate in step (iii b), we 
succeeded in optimizing that step. Byproducts were formed to a lesser extent and the purification 
procedure was dramatically simplified. 
The reaction times are probably reducible, but our aim was first and foremost to get the highest 
yield possible during each respective step. After having conducted several reactions with two different 
assisting bases in step (iii a) and after having isolated and characterized different byproducts formed 
during those reactions, we could develop a proposal for the mechanism of byproduct formation. 
Therefore, we could clearly identify triethylamine as the reason for the formation of byproduct 7 
during step (iii a) that was isolated later, in step (iv), after saponification, as 8. 
Additionally, we could show that also other tertiary alkylamines could act as nucleophiles during a 
nucleophilic aromatic substitution reaction at a heteroaromatic halide. Such a formation of byproducts 
resulting from an initial nucleophilic attack of a tertiary alkylamine and a following elimination of one 
alkyl residue leading to a N,N-dialkylaminyl substituent at the heteroaromatic core was not described 
before during the used conditions. That unexpected fact can be very useful for reaction improvement 
of other nucleophilic aromatic substitution reactions at heteroaromatic halides in general. 
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